GeoVax Labs, Inc. (GOVX) Form S-1 — Sep 17, 2026
GeoVax Labs filed an S-1 registering the resale of up to 11,395,256 shares issuable under an August 2026 warrant held by an institutional investor — a block larger than the company's entire 10,102,871 shares outstanding as of September 14, 2026. The shares stem from an August 25, 2026 warrant inducement in which the holder exercised 5,697,628 existing warrants at a reduced $0.64 price, netting GeoVax about $3,341,000; GeoVax receives no proceeds from the resale but could collect roughly $7.3 million in gross proceeds if the new warrant is fully exercised for cash.
Key figures
- Net Income
- -$21.5 million FY2025; -$9.7 million for six months ended June 30, 2026
- Cash Position
- 3143422
- Gross Proceeds
- None to company from Selling Stockholder resales; up to ~$7.3 million to company if August 2026 Common Warrant fully exercised for cash; ~$3,341,000 net received from the August 2026 inducement
- Offering Price
- No fixed resale price (market-based); underlying August 2026 Common Warrant exercise price $0.64/share; last reported sale $0.43 on September 14, 2026
- Shares Offered
- 11395256
- Employees
- 18
- Cash runway
- into October 2026
- Rd expense fy2025
- $18.1 million
- Rd expense h1 2026
- $7.0 million
- Nasdaq hearing date
- October 13, 2026
- Reverse split ratio
- 1-for-25 (January 12, 2026)
- Warrant exercise price
- 0.64
- Inducement net proceeds
- 3341000
- Shares held in abeyance
- 2964000
- Shares outstanding prior
- 10102871
- Outstanding warrant shares
- 14239319
- Last sale price sept 14 2026
- 0.43
- Total liabilities june 30 2026
- 2882056
- Stockholders equity june 30 2026
- 1760701
- Outstanding warrant weighted avg price
- 0.92
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.